Intellectual Property |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intellectual Property [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| INTELLECTUAL PROPERTY | NOTE 9 – INTELLECTUAL PROPERTY
A third-party independent valuation specialist was asked to determine the value of Global Stem Cell Group, Inc., tangible and intangible assets assuming the offering price was at fair value. In order to perform the purchase price allocation, the tangible and intangible assets were valued as of August 18, 2021.
The Fair Value of the intangible assets as of the Valuation Date is reasonably represented as:
Amortization is computed on straight-line method based on estimated useful lives of 5 years. During the year ended December 31, 2025, and 2024, the Company recorded amortization expense of the intellectual property of $97,540 and $97,540, respectively. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||